Home >> Professional Blog

MiMedx Sponsored Osteoarthritis Study
Using PURION® Processed Amniotic Tissue
Published In Arthritis Research & Therapy

MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development" was authored by Nick Willett, Tanushree Thote, Angela Lin, Shamus Moran, Yazdan Raji, Sanjay Sridaran, Hazel Stevens and Robert Guldberg.

The electronic publication of the study is available at http://arthritis-research.com/content/16/1/R47.

The editor of "Nature Reviews Rheumatology" wrote a highlight article on the study stating that "A paper published in Arthritis Research & Therapy suggests that intra-articular injection of an amniotic membrane allograft can block cartilage damage in a rat medial meniscal transection (MMT) model of OA [Osteoarthritis]." The highlight article can be found at http://www.nature.com/nrrheum/journal/vaop/ncurrent/full/nrrheum.2014.26.html.

"This is the first in a series of pre-clinical work completed on our micronized PURION® Processed amniotic tissue. The results from this in-vivo animal study are extremely promising, and the Company is very pleased to be associated with Georgia Tech and Dr. Guldberg on these studies," said Parker H. "Pete" Petit, Chairman and CEO. "To be recognized in a highlight article in Nature, which is the number one scientific journal worldwide, speaks volumes to the significance of this study," added Mr. Pete Petit.

"This is a sponsored study of a product concept we have had in development that began about 2 years ago. This concept utilizes our micronized PURION® Processed dehydrated human amnion chorion membrane ("dHACM") in an intra-articular injection. This project represents the first MiMedx tissue product that we anticipated would require a different FDA regulatory path from our Section 361 tissue products, and it will likely take the Biologics License Application (BLA) regulatory pathway. We expect follow-on pre-clinical studies for this and other applications of our PURION® Processed tissues over the coming year," commented Bill Taylor, President and COO.

"According to the CDC, osteoarthritis affects an estimated 26.9 million Americans, and there are over 1 million knee and hip replacements each year. The positive impact on the return to normal function and mobility for arthritis sufferers and the potential reduction of arthritis formation could have a large impact on health economics. The conclusions of this study essentially indicate that PURION® Processed ("dHACM") may slow the progression of osteoarthritis. Besides the overall market size, the real opportunity with this product concept is that it could improve the quality of life of many seniors and potentially delay or prevent the need for a knee, hip or shoulder replacement," added Mr. Pete Petit.